Osilodrostat
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Osilodrostat
- Osilodrostat: From an Unrecorded Original Indication to Familial Generalized Lentiginosis (Predicted)
Osilodrostat: From an Unrecorded Original Indication to Familial Generalized Lentiginosis (Predicted)
One-Sentence Summary
The original approved indication for osilodrostat is not recorded in this evidence pack, and its mechanism of action (MOA) is also currently unavailable. The TxGNN model predicts it may be effective for Familial Generalized Lentiginosis, but this is currently supported by 0 clinical trials and 0 publications — the prediction rests entirely on the model’s knowledge-graph score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack |
| Predicted New Indication | Familial Generalized Lentiginosis |
| TxGNN Prediction Score | 98.19% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for osilodrostat is not currently available in this evidence pack, and no original indication is on record either. Without either of these anchors, there is no basis in the supplied data to construct a pharmacological rationale connecting osilodrostat to familial generalized lentiginosis, an extremely rare inherited pigmentary condition.
As the source data itself notes, this disease category has no known mechanistic relationship to osilodrostat’s pharmacological targets, and the TxGNN score reflects graph-embedding similarity rather than a validated biological pathway. No clinical, preclinical, or case-based evidence has been identified to support the association.
This prediction should be treated as a hypothesis-generating signal only, not as evidence of therapeutic plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
Osilodrostat currently has no ARTG entries on record (0 licences), consistent with its “not marketed” status in this jurisdiction. No product, dosage form, or approved indication information is available to summarise.
Safety Considerations
Please refer to the manufacturer’s Product Information for safety data. Note that osilodrostat does not currently hold marketing approval in this jurisdiction, so no locally approved PI, warnings, contraindications, or drug-interaction data are available in this evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature evidence (L5, model-prediction-only), no MOA data to support mechanistic plausibility, and no market presence in this jurisdiction. The predicted indication itself is an extremely rare condition with no biological link to the drug’s known pharmacology in the available data. There is currently nothing to act on beyond the raw model score.
To proceed, the following is needed:
- Osilodrostat’s mechanism of action (from DrugBank or another authoritative source)
- The drug’s original approved indication(s)
- TFDA/TGA-equivalent product information, including warnings and contraindications (currently a Blocking data gap)
- Any preclinical, case-report, or mechanistic literature linking osilodrostat to familial generalized lentiginosis or related pigmentary disorders
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.